Spots Global Cancer Trial Database for decitabine
Every month we try and update this database with for decitabine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant | NCT05799079 | Recurrent Acute... | Venetoclax Decitabine Cedazuridine Bone Marrow Asp... Biospecimen Col... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Clinical Study of Decitabine and Paclitaxel Combination Therapy | NCT03282825 | Advanced Breast... | Decitabine Paclitaxel | 19 Years - | Dong Wha Pharmaceutical Co. Ltd. | |
| A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) | NCT00349596 | Acute Lymphocyt... | Decitabine | - | M.D. Anderson Cancer Center | |
| A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) | NCT00619099 | Myelodysplastic... | decitabine decitabine | 18 Years - | Eisai Inc. | |
| Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | NCT04055844 | Acute Myeloid L... Myeloid and Mon... Myelodysplastic... | Decitabine Ruxolitinib Donor Lymphocyt... | 12 Years - | Masonic Cancer Center, University of Minnesota | |
| Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS | NCT02921061 | Mixed Phenotype... Previously Trea... Recurrent Adult... Recurrent High ... Refractory Acut... Refractory High... Untreated Adult... | Cladribine Cytarabine Decitabine Filgrastim Laboratory Biom... Mitoxantrone Hy... | 18 Years - | Fred Hutchinson Cancer Center | |
| Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | NCT03009240 | Acute Myeloid L... Recurrent Acute... Refractory Acut... Secondary Acute... Therapy-Related... Untreated Adult... | Decitabine Laboratory Biom... Pevonedistat Pharmacological... | 18 Years - | City of Hope Medical Center | |
| Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | NCT00778375 | Acute Myeloid L... Myelodysplastic... | Clofarabine Cytarabine Decitabine | 60 Years - | M.D. Anderson Cancer Center | |
| p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer | NCT02847000 | Metastatic Panc... | Tetrahydrouridi... Decitabine | 18 Years - | Case Comprehensive Cancer Center | |
| Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia | NCT01627041 | Acute Myeloid L... Adult Acute Bas... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Alkylating Agen... Secondary Acute... | Cytarabine Daunorubicin Hy... Decitabine Laboratory Biom... Pharmacological... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | NCT03969446 | Acute Myeloid L... Myelodysplastic... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... | Decitabine Pembrolizumab Venetoclax | 18 Years - | City of Hope Medical Center | |
| Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies | NCT06383572 | Lymphodepleting... Myeloid Maligna... | Cyclophosphamid... Fludarabine pho... Decitabine | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma | NCT04049344 | Metastatic Rena... | Decitabine; Oxa... | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations | NCT03381781 | Acute Myeloid L... P53 Mutation | Decitabine Arsenic Trioxid... Cytarabine | 18 Years - 75 Years | Ruijin Hospital | |
| Trial of Decitabine in Patients With Acute Myeloid Leukemia | NCT00260832 | Acute Myeloid L... | Cytarabine or S... Dacogen (decita... | 65 Years - | Eisai Inc. | |
| Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) | NCT02203773 | Acute Myelogeno... Myelogenous Leu... Treatment Naive... | Posaconazole ABT-199 Decitabine Azacitidine | 60 Years - | AbbVie | |
| Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor | NCT04337606 | Non Hodgkin Lym... | Chidamide Decitabine Camrelizumab | 18 Years - 65 Years | Chinese PLA General Hospital | |
| Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies | NCT03771222 | Donor Lymphocyt... Peripheral Bloo... Relapse Graft-versus-ho... Decitabine | Prophylactic DL... | 14 Years - 65 Years | Chinese PLA General Hospital | |
| Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts | NCT03974217 | Leukemia | Talazoparib Decitabine | 18 Years - | Dana-Farber Cancer Institute | |
| Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | NCT04146038 | Acute Myeloid L... Chronic Myelomo... Myeloblasts 10 ... Myelodysplastic... Myeloproliferat... Recurrent Acute... Refractory Acut... Secondary Acute... | Azacitidine Decitabine Salsalate Venetoclax | 18 Years - | Rutgers, The State University of New Jersey | |
| PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma | NCT05137886 | Hodgkin Lymphom... Relapse Refractory Hodg... | PD-1 inhibitor | 18 Years - 65 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML) | NCT00398983 | Acute Myelogeno... | Decitabine | 18 Years - | M.D. Anderson Cancer Center | |
| Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT01846624 | Acute Myeloid L... AML (Adult) Wit... AML (Adult) Wit... AML (Adult) Wit... AML (Adult) Wit... AML (Adult) Wit... Secondary AML (... Untreated AML (... | Decitabine Midostaurin | 60 Years - | Stanford University | |
| Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies | NCT06383572 | Lymphodepleting... Myeloid Maligna... | Cyclophosphamid... Fludarabine pho... Decitabine | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients | NCT02109744 | Acute Myelogeno... | Decitabine | 18 Years - 70 Years | University of Rochester | |
| Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | NCT02441803 | Leukemia | Busulfan Fludarabine Clofarabine Total Body Irra... Thymoglobulin Stem Cell Infus... Cyclophosphamid... Tacrolimus Mycophenolate m... Decitabine Cytarabine Idarubicin | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
| An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome | NCT01400633 | Myelodysplastic... | decitabine inje... | 20 Years - | Janssen Korea, Ltd., Korea | |
| Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS) | NCT03377725 | Myelodysplastic... P53 Mutation | Decitabine Arsenic Trioxid... | 18 Years - 75 Years | Ruijin Hospital | |
| Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant | NCT00986804 | Leukemia, Myelo... Myelodysplastic... | Decitabine | 18 Years - | Washington University School of Medicine | |
| Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00079378 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Recurrent Small... Refractory Chro... Untreated Adult... | decitabine valproic acid pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Epigenetic Reprogramming in Relapse/Refractory AML | NCT03263936 | Acute Myelogeno... | Decitabine Vorinostat Filgrastim (G-C... Fludarabine Cytarabine | 1 Year - 25 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | NCT04055844 | Acute Myeloid L... Myeloid and Mon... Myelodysplastic... | Decitabine Ruxolitinib Donor Lymphocyt... | 12 Years - | Masonic Cancer Center, University of Minnesota | |
| A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes | NCT00260065 | Myelodysplastic... | Decitabine | 18 Years - | Eisai Inc. | |
| Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia | NCT00671697 | Myelodysplastic... | Arsenic Trioxid... Decitabine | 18 Years - | Washington University School of Medicine | |
| Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML | NCT02073838 | Acute Myeloid L... | Ribavirin Vismodegib Decitabine | 18 Years - | Jewish General Hospital | |
| Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) | NCT03303339 | Acute Myeloid L... | Onvansertib Cytarabine Decitabine | 18 Years - | Cardiff Oncology | |
| An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS) | NCT00744757 | Myelodysplastic... | Decitabine | 18 Years - | Johnson & Johnson Taiwan Ltd | |
| Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer | NCT00084981 | Recurrent Non-s... Stage IV Non-sm... | decitabine valproic acid pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia | NCT04051996 | ACUTE MYELOID L... | Glasdegib Decitabine | 18 Years - | Yale University | |
| Genotype-guided Treatment in DLBCL | NCT05351346 | Diffuse Large B... | Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone Orelabrutinib Lenalidomide Decitabine | 18 Years - 80 Years | Ruijin Hospital | |
| Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer. | NCT03467178 | Recurrent, Plat... | Decitabine Carboplatin Pegylated Lipos... Gemcitabine Paclitaxel | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT | NCT04098653 | Allogeneic Hema... Conditioning Myeloid Tumors | Decitabine Busulfan (BU) Cyclophosphamid... | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Decitabine Combined With Gemcitabine in First-line Treatment of AdvancedPancreatic Cancer | NCT02685228 | Pancreatic Canc... | Decitabine Gemcitabine | 18 Years - 70 Years | The First Hospital of Jilin University | |
| Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT01707004 | Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... | decitabine fludarabine pho... busulfan cyclophosphamid... tacrolimus mycophenolate m... filgrastim total-body irra... allogeneic bone... laboratory biom... | 18 Years - 75 Years | University of Wisconsin, Madison | |
| Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT | NCT04098653 | Allogeneic Hema... Conditioning Myeloid Tumors | Decitabine Busulfan (BU) Cyclophosphamid... | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies | NCT00037817 | Advanced Esopha... Primary Small C... Non-Small-Cell ... Pleural Mesothe... Cancers of Non-... | Decitabine Depsipeptide Celecoxib | 18 Years - 65 Years | National Institutes of Health Clinical Center (CC) | |
| Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML | NCT00538876 | Acute Myeloid L... | decitabine | 18 Years - | Weill Medical College of Cornell University | |
| Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients | NCT01633099 | Untreated Adult... Effect of Drugs Drug Safety | Decitabine | 60 Years - | ChineseAMS | |
| Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk | NCT00906334 | Myelodysplastic... | ON 01910.Na ON 01910.Na | 18 Years - | Traws Pharma, Inc. | |
| A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT01546038 | Acute Myeloid L... | PF-04449913 Low dose ARA-C ... PF-04449913 Decitabine PF-04449913 Daunorubicin Cytarabine PF-04449913 Daunorubicin Cytarabine PF-04449913 Low dose ARA-C ... | 18 Years - | Pfizer | |
| A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes | NCT04985656 | Myelodysplastic... | Pevonedistat Decitabine Cedazuridine | 18 Years - | Takeda | |
| Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia | NCT04353479 | Acute Myeloid L... | Camrelizumab(SH... Decitabine | 60 Years - 75 Years | Shanghai Jiao Tong University School of Medicine | |
| Biomarker Guided Treatment in DLBCL | NCT04025593 | Diffuse Large B... | Cyclophosphamid... Rituximab Doxorubicin Vincristine Prednisone Ibrutinib Lenalidomide chidamide decitabine | 18 Years - 80 Years | Ruijin Hospital | |
| Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | NCT00801489 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... de Novo Myelody... High Risk Myelo... Inv(16) Myelodysplastic... t(16;16) t(8;21) Untreated Adult... | Cytarabine Decitabine Filgrastim-sndz Fludarabine Pho... Gemtuzumab Ozog... Idarubicin Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS | NCT01417767 | Myelodysplastic... | CHG regimen 5-aza-deoxycyti... | 16 Years - 80 Years | Shanghai 6th People's Hospital | |
| Clinical Study of Decitabine and Paclitaxel Combination Therapy | NCT03282825 | Advanced Breast... | Decitabine Paclitaxel | 19 Years - | Dong Wha Pharmaceutical Co. Ltd. | |
| Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer | NCT00477386 | Ovarian Cancer | decitabine | 18 Years - | Indiana University | |
| A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | NCT04155580 | Acute Myeloid L... | ASTX660 ASTX727 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) | NCT03026842 | Acute Myeloid L... | Decitabine Daunorubicin, C... Mitoxantrone, C... Aclacinomycin, ... | 18 Years - 60 Years | The First Hospital of Jilin University | |
| HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML | NCT05586074 | Leukemia, Acute... | Clifutinib LoDAC Azacitidine Decitabine Ara-C±IDA FLAG-IDA | 18 Years - | Sunshine Lake Pharma Co., Ltd. | |
| Trial of Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | NCT00760084 | Acute Myelogeno... Myelodysplastic... | Decitabine | 18 Years - | Eisai Inc. | |
| Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS | NCT01417767 | Myelodysplastic... | CHG regimen 5-aza-deoxycyti... | 16 Years - 80 Years | Shanghai 6th People's Hospital | |
| Decitabine in Treating Patients With Advanced Solid Tumors | NCT00030615 | Male Breast Can... Recurrent Bladd... Recurrent Breas... Recurrent Melan... Stage III Melan... Stage IV Bladde... Stage IV Breast... Stage IV Melano... Unspecified Adu... | decitabine pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL | NCT03240211 | PTCL CTCL | Pembrolizumab Pralatrexate Decitabine | 18 Years - 90 Years | University of Virginia | |
| Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | NCT02890329 | Previously Trea... Recurrent Acute... Recurrent Acute... Recurrent Myelo... Refractory Acut... Refractory Myel... Secondary Acute... Secondary Myelo... | Decitabine Ipilimumab | 18 Years - | National Cancer Institute (NCI) | |
| Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT | NCT03596892 | Allogeneic Hema... Conditions Mixed-lineage-l... | Decitabine Busulfan (BU) Cyclophosphamid... | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS) | NCT00941109 | Myelodysplastic... | decitabine decitabine decitabine decitabine | 18 Years - | Eisai Inc. | |
| Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax | NCT05222984 | Recurrent Acute... Refractory Acut... | Decitabine Navitoclax Venetoclax | 16 Years - | City of Hope Medical Center | |
| A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | NCT03941964 | Acute Myeloid L... Cancer | Venetoclax Azacitidine Decitabine | 12 Years - | AbbVie | |
| Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia | NCT00703300 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Secondary Acute... Untreated Adult... | bortezomib decitabine pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk | NCT01720225 | Leukemia | Decitabine Azacitidine | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia | NCT06401603 | Advanced Chroni... Philadelphia Ch... | Decitabine Listaftoclax Olverembatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors | NCT00701298 | Unspecified Adu... | peginterferon a... decitabine laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes | NCT01674985 | Myelodysplastic... | Microtransplant... | 10 Years - 90 Years | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | |
| Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion | NCT00791271 | Melanoma | Decitabine Pegylated Inter... | 18 Years - | M.D. Anderson Cancer Center | |
| Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML | NCT04493099 | Recurrent Acute... Refractory Acut... | Alvocidib Hydro... Decitabine Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). | NCT03946670 | Myelodysplastic... | MBG453 Placebo Hypomethylating... | 18 Years - | Novartis | |
| A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) | NCT05829226 | AML, Adult Recu... MDS | LYT-200 Venetoclax Azacitidine Decitabine | 18 Years - | PureTech | |
| Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects | NCT01177540 | Pediatric Acute... | Decitabine Decitabine | 1 Year - 16 Years | Eisai Inc. | |
| Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00748527 | Fallopian Tube ... Ovarian Cancer Peritoneal Cavi... | carboplatin decitabine | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
